CN1845916A - 作为选择性黑素浓集激素受体拮抗剂用于治疗肥胖症及相关疾病的2－取代苯并咪唑哌啶类似物 - Google Patents

作为选择性黑素浓集激素受体拮抗剂用于治疗肥胖症及相关疾病的2－取代苯并咪唑哌啶类似物 Download PDF

Info

Publication number
CN1845916A
CN1845916A CNA2004800249377A CN200480024937A CN1845916A CN 1845916 A CN1845916 A CN 1845916A CN A2004800249377 A CNA2004800249377 A CN A2004800249377A CN 200480024937 A CN200480024937 A CN 200480024937A CN 1845916 A CN1845916 A CN 1845916A
Authority
CN
China
Prior art keywords
compound
substituted
alkyl
pharmaceutically acceptable
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800249377A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·伯内特
吴文良
T·K·萨西库马
W·J·格林李
M·A·卡普伦
T·郭
R·亨特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia Drug Discovery Inc
Merck Sharp and Dohme LLC
Original Assignee
Pharmacopeia Drug Discovery Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery Inc, Schering Corp filed Critical Pharmacopeia Drug Discovery Inc
Publication of CN1845916A publication Critical patent/CN1845916A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800249377A 2003-08-29 2004-08-26 作为选择性黑素浓集激素受体拮抗剂用于治疗肥胖症及相关疾病的2－取代苯并咪唑哌啶类似物 Pending CN1845916A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49887603P 2003-08-29 2003-08-29
US60/498,876 2003-08-29

Publications (1)

Publication Number Publication Date
CN1845916A true CN1845916A (zh) 2006-10-11

Family

ID=34272746

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800249377A Pending CN1845916A (zh) 2003-08-29 2004-08-26 作为选择性黑素浓集激素受体拮抗剂用于治疗肥胖症及相关疾病的2－取代苯并咪唑哌啶类似物

Country Status (10)

Country Link
US (1) US7511146B2 (enExample)
EP (1) EP1664022B1 (enExample)
JP (1) JP4672662B2 (enExample)
CN (1) CN1845916A (enExample)
AR (1) AR045496A1 (enExample)
AT (1) ATE512959T1 (enExample)
CA (1) CA2536929C (enExample)
MX (1) MXPA06002372A (enExample)
TW (1) TW200524902A (enExample)
WO (1) WO2005023798A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104860919A (zh) * 2015-03-26 2015-08-26 天津药物研究院有限公司 含哌啶的苯并咪唑衍生物及其制备方法和用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516407A (pt) * 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
KR20080027908A (ko) * 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
AR064735A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
SI2114933T1 (sl) * 2007-01-04 2012-01-31 Prosidion Ltd Windrush Court Piperidinski gpcr-agonisti
AR064736A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
CN102239158A (zh) * 2008-12-04 2011-11-09 葛兰素集团有限公司 螺旋二氢吲哚的制备方法及其前体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
MXPA03009353A (es) * 2001-04-12 2004-02-12 Pharmacopeia Inc Aril y biaril piperidinas utilizadas como antagonistas de mch.
DE60234116D1 (de) * 2001-11-26 2009-12-03 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104860919A (zh) * 2015-03-26 2015-08-26 天津药物研究院有限公司 含哌啶的苯并咪唑衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CA2536929C (en) 2010-09-28
US20050054628A1 (en) 2005-03-10
CA2536929A1 (en) 2005-03-17
AR045496A1 (es) 2005-11-02
TW200524902A (en) 2005-08-01
US7511146B2 (en) 2009-03-31
ATE512959T1 (de) 2011-07-15
JP2007504146A (ja) 2007-03-01
EP1664022B1 (en) 2011-06-15
JP4672662B2 (ja) 2011-04-20
WO2005023798A1 (en) 2005-03-17
MXPA06002372A (es) 2006-06-20
EP1664022A1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
CN1305872C (zh) 喹唑啉类化合物的制备方法
CN1098263C (zh) 吡啶－2－基－甲胺衍生物、其制备方法及其作为药物的用途
CN1117082C (zh) 具有抗癌和细胞活素抑制活性的取代咪唑类化合物
CN1592739A (zh) 用于治疗肥胖和cns疾病的基于哌啶的mch拮抗剂
CN1558764A (zh) 取代脲类神经肽yy5受体拮抗剂
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
CN1498205A (zh) 具有mch调节活性的芳基和二芳基化合物
CN1103770C (zh) 喹喔啉二酮化合物
CN1434811A (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
CN1184425A (zh) 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
CN1503673A (zh) 消炎药
CN1642938A (zh) 新化合物
CN1800186A (zh) 腺苷A2a受体拮抗剂
CN1409703A (zh) 4－氨基哌啶衍生物和它们作为药物的用途
CN1482912A (zh) 杂芳基脲神经肽yy5受体拮抗剂
CN1886380A (zh) 苯并咪唑化合物
CN1901917A (zh) 作为糖原磷酸化酶抑制剂用于治疗糖尿病和肥胖症的(3－氧代－3，4－二氢－喹喔啉－2－基－氨基)－苯甲酰胺衍生物和相关化合物
CN1585749A (zh) 类大麻苷受体配体
CN1305862C (zh) 作为腺苷受体配体的7－氨基苯并噻唑衍生物
CN1213306A (zh) 新的取代咪唑化合物
CN1596258A (zh) 腺A2α受体拮抗剂
CN1365281A (zh) 金属蛋白酶抑制剂
CN1639147A (zh) 4,5－二氢－吡唑并[3,4－c]吡啶－2－酮类化合物的合成
CN1658874A (zh) 用作组胺h3拮抗剂的(1－4－哌啶基)苯并咪唑衍生物
CN1575169A (zh) 用于治疗肥胖的mch拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication